TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ACR 20 response at week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total radiographic scores of hands and feet at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety as assessed by the Pediatric 7 question survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent's prediction of child's anxiety in the dental office as assessed by survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Energy intake during buffet meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fold-change From Baseline in Maximum Cystometric Capacity Post-dose on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Who Discontinued Use of Study Drug Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of BIBF 1120
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of iron overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Vancouver Scar Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Xenon concentrations at which consciousness is lost and regained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Partial-onset Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Lipid Content of the Liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diameter of the Nervae medianus in the Carpal Tunnel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transdiaphragmatic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diaphragmatic conformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Muscular strength tests of hip and knee muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle thickness measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle activation of knee, hip and foot muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenolic metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to detect a 2-point NRS scale difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serious TEAEs (STEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Severe (Grade 3 or Higher) TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuations From the Trial Due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Standardized Baseline-Adjusted FEV1 AUEC0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement and remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of the close relative
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experience of receiving a diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Extubation Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probing pocket depths (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes to the Surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in small intestine TCR repertoire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in peripheral blood TCR repertoire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes from baseline in small intestine and peripheral blood transcriptome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Associated symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of vitamin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Failure rates in patients undergoing cardioversion for atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GI response to lipid emulsions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lymphocytes Laboratory Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive Predictive Value of tests for Coronary artery disease detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Downstream resource utilisation following allocated functional tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in reference tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Moderate-to-severe Acute Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume of epidural local anaesthetic administrated during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Glucose Uptake in Leg Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance score based on the checklist for each device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full pharmacokinetic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Place Archbars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone healing in the docking site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Wolf motor function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (For MLD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (For ALD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of I-Gel malposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of severe asthma patients eligible for biologic treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of clinical response and/or remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free Piperacillin Concentration Maintained Above the MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free Piperacillin Concentration Maintained at a Level Fourfold the MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients requiring sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Oxidative Stress Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum bactericidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: velocities of shear wave elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: relapse rate of OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Adherence to NICE-UK Guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of Blood Cortisol from baseline to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response
Endpoint domain: Mortality/survival
Primary endpoint: Changes in brain activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with serum T3 concentrations below normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Arteriovenous Fistula Failure to Mature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Implant Stability as Measured by the Osstell Implant Stability Quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in temporal stability of neural measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate of tumor
Endpoint domain: Mortality/survival
Primary endpoint: Time taken for polyp removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acoustic rhinometry result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measure of functional level, emotional status, community activities, and perceived quality of well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Days alive in 30 days without vasopressors/inotropes or hyperlactatemia
Endpoint domain: Mortality/survival
Primary endpoint: Change in ADAS-Cog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of osimertinib and alisertib combination (Arm A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of osimertinib and sapanisertib combination (Arm B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAHS (non-arthritic hip score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux Disease Questionnaire (RDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of systolic and diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV mass in responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COVID-19 by positive PCR in cord blood and/or positive serologies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effectiveness of a single ablative procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HbA1c (%) Measured at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Weight Change From Baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in SF 36v2 Quality of Life Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Concentration of Serotype-Specific IgG Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change from baseline in best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Severe Neonatal Morbidity and Perinatal Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participant Infants Requiring Respiratory Support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Infants With Apgar Score ≤3 at 5 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Tmax of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Qualitative Splenic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Central Aortic Pressure (CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction of communication quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of NAT2 phenotypically driven dosing regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of Amonafide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic profile of Amonafide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nephrotic state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: side effects of cyclosporin A
Endpoint domain: Adverse events/effects
Primary endpoint: SNOT 22 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Luckyvec and Glivec
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy proven antibody mediated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in 1-Hour Postdose Percent Predicted Morning FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adequacy of lipid-lowering prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in average pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Healing of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in surgical plan due to FDOPA-PET addition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24-month Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Tolerability of home ScIG therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Analyte Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC [0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Maternal Complications of Pregnancy, Labor and Delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Births With Neonatal Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Binocular Uncorrected Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversing vasomotor and fibrinolytic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in ABC-H Score
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Pain Catastrophizing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction of the size of the caries lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigational agent-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Longest diameter of target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ocular Allergic signs and symptoms Diary Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: resting postoperative pain at 24hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent stent volume obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility and acceptability of massage therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major Adverse Limb Event (MALE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Meeting Dose Criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Cross Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Alvocade® therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Alvocade® therapy
Endpoint domain: Physiological/clinical
Primary endpoint: Effective Dose for 50% of Patients for Successful Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subsequent Extubation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in 7-Day physical activity recall interview
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Temperature measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the Nomogram in predicting lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Observed eating session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impulse Oscillometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and tolerability of SRA-444
Endpoint domain: Adverse events/effects
Primary endpoint: Enuresis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scores (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Study enrollment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intervention session attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety (i.e., adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Blood Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time spent in safe blood glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of peri-implant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Score of Rosacea Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Severe Visual Distortions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Father Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Behavior and Emotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rate (> 30% reduction in VASPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in capillary malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of sensor glucose readings within range of 70-180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aggregate cardiovascular and respiratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sedation/agitation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation/responsiveness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes